Abstract：
Male breast cancer (MBC) is rare and little is known about its biological behavior. In this study we described clinical characteristics and prognosis of MBC and evaluated roles of different factors between MBC and female breast cancer (FBC).
We retrospectively reviewed 42 MBC patients matched with 84 consecutive FBC patients with similar year, age, tumor, node, metastases (TNM) stage, and estrogen receptor (ER) expression from 2003 to 2016. Their clinical characteristics, treatments, and prognosis were analyzed, and immunohistochemistry for androgen receptor (AR), dachshund 1 (DACH1), sine oculis 1 (SIX1), eyes absent 1, B-cell lymphoma-2, and p53 were performed on paraffin sections.
MBC constituted 0.56% (42 of 7561) of consecutive breast cancer and had a median age of 55 years. The 14 paraffin samples from men and 28 from women expressed all the assessed proteins, and DACH1 was significantly higher in women (P = .043). Body mass index (P = .023) and DACH1 (P = .034) were correlated with MBC prognosis, whereas the expression of AR (P = .049), SIX1 (P = .048), surgery (P < .001), and chemotherapy (P = .001) were important for FBC in addition to already known factors: tumor size and location, TNM stage (lymph nodes and organ metastasis), radiotherapy, and ER and human epidermalgrowth factor receptor-2 (HER2) expression. No distinct difference in recurrence was observed between MBC and FBC (P = .667).
In this study we found that DACH1 was expressed less in MBC and HER2 was expressed more in FBC. They were respectively correlated with MBC and FBC prognosis. Although no significant differences were observed between MBC and FBC prognosis, DACH1, SIX1, and AR expression requires greater attention to develop treatment strategies for MBC and FBC.
We retrospectively reviewed 42 MBC patients matched with 84 consecutive FBC patients with similar year, age, tumor, node, metastases (TNM) stage, and estrogen receptor (ER) expression from 2003 to 2016. Their clinical characteristics, treatments, and prognosis were analyzed, and immunohistochemistry for androgen receptor (AR), dachshund 1 (DACH1), sine oculis 1 (SIX1), eyes absent 1, B-cell lymphoma-2, and p53 were performed on paraffin sections.
MBC constituted 0.56% (42 of 7561) of consecutive breast cancer and had a median age of 55 years. The 14 paraffin samples from men and 28 from women expressed all the assessed proteins, and DACH1 was significantly higher in women (P = .043). Body mass index (P = .023) and DACH1 (P = .034) were correlated with MBC prognosis, whereas the expression of AR (P = .049), SIX1 (P = .048), surgery (P < .001), and chemotherapy (P = .001) were important for FBC in addition to already known factors: tumor size and location, TNM stage (lymph nodes and organ metastasis), radiotherapy, and ER and human epidermalgrowth factor receptor-2 (HER2) expression. No distinct difference in recurrence was observed between MBC and FBC (P = .667).
In this study we found that DACH1 was expressed less in MBC and HER2 was expressed more in FBC. They were respectively correlated with MBC and FBC prognosis. Although no significant differences were observed between MBC and FBC prognosis, DACH1, SIX1, and AR expression requires greater attention to develop treatment strategies for MBC and FBC.
摘要：
男性乳腺癌（MBC）很少见，对其生物学行为知之甚少。在这项研究中，我们描述了MBC的临床特征和预后，并评估了不同因素在MBC和女性乳腺癌（FBC）之间的作用。
我们回顾性分析了42例MBC患者与84例连续FBC患者的相似年份，年龄,肿瘤，节点,转移（TNM）分期，和雌激素受体（ER）表达从2003年到2016年。他们的临床特征，治疗,并对预后进行了分析，和雄激素受体（AR）的免疫组织化学，腊肠犬1（DACH1），正弦眼波1（SIX1），在石蜡切片上进行眼睛缺失1，B细胞淋巴瘤2和p53。
MBC占连续乳腺癌的0.56%（42/7561），中位年龄为55岁。来自男性的14个石蜡样本和来自女性的28个石蜡样本表达了所有评估的蛋白质，DACH1在女性中显著高于女性（P=0.043）。体重指数（P=0.023）和DACH1（P=0.034）与MBC预后相关，而AR的表达(P=0.049)，SIX1（P=.048），手术（P<.001），化疗（P=0.001）对FBC很重要，除了已知的因素：肿瘤大小和位置，TNM分期（淋巴结和器官转移），放射治疗,和ER和人表皮生长因子受体2（HER2）的表达。在MBC和FBC之间没有观察到明显的复发差异(P=.667)。
在这项研究中，我们发现DACH1在MBC中表达较少，而HER2在FBC中表达较多。它们分别与MBC和FBC预后相关。虽然MBC和FBC预后之间没有观察到显著差异,DACH1，SIX1和AR表达需要更多的关注来开发MBC和FBC的治疗策略。
我们回顾性分析了42例MBC患者与84例连续FBC患者的相似年份，年龄,肿瘤，节点,转移（TNM）分期，和雌激素受体（ER）表达从2003年到2016年。他们的临床特征，治疗,并对预后进行了分析，和雄激素受体（AR）的免疫组织化学，腊肠犬1（DACH1），正弦眼波1（SIX1），在石蜡切片上进行眼睛缺失1，B细胞淋巴瘤2和p53。
MBC占连续乳腺癌的0.56%（42/7561），中位年龄为55岁。来自男性的14个石蜡样本和来自女性的28个石蜡样本表达了所有评估的蛋白质，DACH1在女性中显著高于女性（P=0.043）。体重指数（P=0.023）和DACH1（P=0.034）与MBC预后相关，而AR的表达(P=0.049)，SIX1（P=.048），手术（P<.001），化疗（P=0.001）对FBC很重要，除了已知的因素：肿瘤大小和位置，TNM分期（淋巴结和器官转移），放射治疗,和ER和人表皮生长因子受体2（HER2）的表达。在MBC和FBC之间没有观察到明显的复发差异(P=.667)。
在这项研究中，我们发现DACH1在MBC中表达较少，而HER2在FBC中表达较多。它们分别与MBC和FBC预后相关。虽然MBC和FBC预后之间没有观察到显著差异,DACH1，SIX1和AR表达需要更多的关注来开发MBC和FBC的治疗策略。
